NAV
$62.00
AUM
$8.5M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +6.97% | +8.71% | +11.79% | +23.09% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 7.93% |
| 2 | ABBV | AbbVie Inc | 7.28% |
| 3 | UNH | UnitedHealth Group Inc | 6.18% |
| 4 | JNJ | Johnson & Johnson | 4.64% |
| 5 | MRK | Merck & Co Inc | 4.50% |
| 6 | AZN.L | AstraZeneca PLC | 4.39% |
| 7 | BMY | Bristol-Myers Squibb Co | 3.34% |
| 8 | TMO | Thermo Fisher Scientific Inc | 3.22% |
| 9 | CVS | CVS Health Corp | 2.91% |
| 10 | NOVO-B.CO | Novo Nordisk AS Class B | 2.80% |
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
Inception Date: 2023-11-01